MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview

MaxCyte

10/08/2026 21:40

MaxCyte Inc MXCT.OQ MXCT.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 for the period ending June 30 2026
The Rockville Maryland-based  company is expected to report a 23.9% decrease in revenue to $6.475 million from $8.51 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for MaxCyte Inc is for a loss of 9 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for MaxCyte Inc is $4.50, about 281.4% above its last closing price of $1.18
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.08
-0.08
-0.04
Beat
50
Dec. 31 2026
-0.08
-0.06
Beat
25
Sep. 30 2025
-0.11
-0.11
-0.09
Beat
18.2​
Jun. 30 2025
-0.10
-0.10
-0.12
Missed
-16.1
​​Mar. 31 2025
-0.11
-0.10
-0.10
Met
4.8
Dec. 31 2024
-0.11
-0.12
-0.10
Beat
18​
Sep. 30 2024
-0.12
-0.12
-0.11
Beat
10.8
Jun. 30 2024
-0.13
-0.13
-0.09
Beat
28.9
This summary was machine generated August 10 at 20:40 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)